An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.

• Status: Completed
• Trial end date: 2016-01-08
• Target enrollment: 0
• Participant gender: All

Summary

The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Active choroidal neovascularization (CNV)

• Active macular edema (ME)

• Rubeosis iridis/neovascular glaucoma.

• Proliferative diabetic retinopathy requiring vitrectomy.

Exclusion Criteria:

• wet Age-related macular degeneration

• pathologic myopia

• pseudoxanthoma elasticum

• diabetic macular edema

• retinal vein occlusion

• < 18 years of age

• History of hypersensitivity to ranibizumab

• Use of any systemic anti-angiogenic drugs 3 months before inclusion

• Women of child-bearing potential and Pregnant or nursing (lactating) women.

• Active or suspected ocular infection